
(1S,2S)-2-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid | CAS:143679-80-5
(1S,2S)-2-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid
- 名称:(1S,2S)-2-[(叔丁氧羰基)氨基]环戊烷羧酸 | (1S,2S)-2-[(tert-Butoxycarbonyl)amino]cyclopentanecarboxylic acid
- CAS号:143679-80-5
- 别名:(1S-trans)-2-[[(1,1-Dimethylethoxy)carbonyl]amino]cyclopentanecarboxylic acid
- 分子式:C11H19NO4
- 分子量:229.27
- EINESC号:
产品描述
物理化学性质
密度 | 1.15 |
---|
安全数据
没有数据 | 没有数据 |
---|
产品合成路线
名称 | CAS号 |
---|
更多
文章
同行评议文献
Secretion of hydrolytic enzymes by fungal strains, isolated from patients with malignant tumors of head and neck, before, during and after radiotherapy.Salah Moqbil et al.Annals of parasitology, 58(1), 27-35 (2012-10-26)
Prevalence of Fabry's disease within hemodialysis patients in Spain.Julio Herrera et al.Clinical nephrology, 81(2), 112-120 (2013-12-25)
Fabry disease: dose matters.David G Warnock et al.Journal of the American Society of Nephrology : JASN, 25(4), 653-655 (2014-02-22)
[Interrelation of alpha-D-fucosidase and alpha-D-galactosidase activities in man and animals].G Ia Vidershaîn et al.Doklady Akademii nauk SSSR, 231(2), 486-488 (1976-01-01)
Angiokeratomas - When is a few too many?Colm O'Mahony et al.International journal of STD & AIDS, 25(5), 378-379 (2013-10-10)
Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease.Ester M Pereira et al.Gene, 536(1), 118-122 (2013-12-18)
Fabry disease: dose matters.David G Warnock et al.Journal of the American Society of Nephrology : JASN, 25(4), 653-655 (2014-02-22)
Cloning, heterologous expression, and characterization of novel protease-resistant α-galactosidase from new Sphingomonas strain.Junpei Zhou et al.Journal of microbiology and biotechnology, 22(11), 1532-1539 (2012-11-06)
Streptococcus danieliae sp. nov., a novel bacterium isolated from the caecum of a mouse.Thomas Clavel et al.Archives of microbiology, 195(1), 43-49 (2012-10-12)
Prevalence of Fabry's disease within hemodialysis patients in Spain.Julio Herrera et al.Clinical nephrology, 81(2), 112-120 (2013-12-25)
Screening human genes for small alterations performing an enzymatic cleavage mismatched analysis (ECMA) protocol.Nikolaos Vogiatzakis et al.Molecular biotechnology, 55(1), 1-9 (2013-08-13)
Mir-20a regulates in vitro mineralization and BMP signaling pathway by targeting BMP-2 transcript in fish.Daniel M Tiago et al.Archives of biochemistry and biophysics, 543, 23-30 (2013-12-24)
Reference intervals of α-glycosidase, β-glycosidase, and α-galactosidase in dried blood spot in a Turkish newborn population.Ozan Aldemir et al.European journal of pediatrics, 172(9), 1221-1227 (2013-05-11)
Fabry disease: is there a role for enzyme replacement therapy?A B Mehta Journal of internal medicine, 274(4), 329-330 (2013-05-15)
Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease.Ester M Pereira et al.Gene, 536(1), 118-122 (2013-12-18)
Delayed anaphylactic reaction to mammalian meat.K Sekiya et al.Journal of investigational allergology & clinical immunology, 22(6), 446-447 (2012-10-30)
Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.Saskia M Rombach et al.PloS one, 7(10), e47805-e47805 (2012-10-25)
A thermodynamic assay to test pharmacological chaperones for Fabry disease.Giuseppina Andreotti et al.Biochimica et biophysica acta, 1840(3), 1214-1224 (2013-12-24)
Streptococcus dentisani sp. nov., a novel member of the mitis group.Anny Camelo-Castillo et al.International journal of systematic and evolutionary microbiology, 64(Pt 1), 60-65 (2013-09-06)
[Home-based infusion therapy--a feasible approach for chronically ill patients? A new path to provide superior patient care exemplified for Fabry's disease].M Beck et al.Deutsche medizinische Wochenschrift (1946), 138(46), 2345-2350 (2013-11-07)
Enzyme replacement therapy for Anderson-Fabry disease.Regina P El Dib et al.The Cochrane database of systematic reviews, 2(2), CD006663-CD006663 (2013-03-02)
Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers.Janet Hsu et al.Journal of biomedical nanotechnology, 10(2), 345-354 (2014-04-18)
Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation.Ilyas Okur et al.Gene, 527(1), 42-47 (2013-06-13)
Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.Giovanni Duro et al.Gene, 535(2), 365-369 (2013-10-22)
March-in rights under the Bayh-Dole Act: the NIH's paper tiger?William O'Brien Seton Hall law review, 43(4), 1403-1432 (2013-12-07)
[Genetic and clinical study of three Chinese pedigrees with Fabry disease].Mao-lu Tian et al.Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 30(2), 185-188 (2013-04-10)
Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.Frank Weidemann et al.Journal of the American Society of Nephrology : JASN, 25(4), 837-849 (2014-02-22)
Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.Shinkyu Choi et al.Arteriosclerosis, thrombosis, and vascular biology, 34(1), 81-89 (2013-10-26)
Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.Antonio Pisani et al.Molecular genetics and metabolism, 107(3), 267-275 (2012-09-12)
Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy.Aritz Pérez Ruiz de Garibay et al.Drug design, development and therapy, 6, 303-310 (2012-11-03)
Fabry's disease--a comprehensive review on pathogenesis, diagnosis and treatment.Huma Mamun Mahmud JPMA. The Journal of the Pakistan Medical Association, 64(2), 189-194 (2014-03-20)
What lies beneath: Fabry nephropathy in a female patient with severe cerebrovascular disease.Elen A Romão et al.Clinical nephrology, 79(4), 330-334 (2013-03-30)
Cicer α-galactosidase immobilization onto functionalized graphene nanosheets using response surface method and its applications.Neelesh Singh et al.Food chemistry, 142, 430-438 (2013-09-05)
Alpha-galactosidase from Mortierella vinacea. Crystallization and properties.H Suzuki et al.The Journal of biological chemistry, 245(4), 781-786 (1970-02-25)
Bifidobacterial α-galactosidase with unique carbohydrate-binding module specifically acts on blood group B antigen.Takura Wakinaka et al.Glycobiology, 23(2), 232-240 (2012-10-24)
Diagnosing lysosomal storage disorders: Fabry disease.Olaf A Bodamer et al.Current protocols in human genetics, Chapter 17, Unit17-Unit17 (2013-04-19)
The molecular mechanism of thermostable α-galactosidases AgaA and AgaB explained by x-ray crystallography and mutational studies.Romain Merceron et al.The Journal of biological chemistry, 287(47), 39642-39652 (2012-09-27)
Raffinose metabolism in Escherichia coli K12. Purification and properties of a new alpha-galactosidase specified by a transmissible plasmid.K Schmid et al.European journal of biochemistry, 67(1), 95-104 (1976-08-01)
Red meat allergy in Sweden: association with tick sensitization and B-negative blood groups.Carl Hamsten et al.The Journal of allergy and clinical immunology, 132(6), 1431-1434 (2013-10-08)
No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene.Masahisa Kobayashi et al.Molecular genetics and metabolism, 107(4), 711-715 (2012-11-14)
Agalsidase benefits renal histology in young patients with Fabry disease.Camilla Tøndel et al.Journal of the American Society of Nephrology : JASN, 24(1), 137-148 (2013-01-01)
Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.Dominique P Germain et al.Orphanet journal of rare diseases, 7, 91-91 (2012-11-28)
Fabry disease with atypical neurological presentation: report of a case.Costanza Simoncini et al.The neurologist, 18(6), 413-414 (2012-11-02)
Application of α-N-acetylgalactosaminidase and α-galactosidase in AB to O red blood cells conversion.Hongwei Gao et al.Artificial cells, nanomedicine, and biotechnology, 41(1), 32-36 (2012-10-04)
A revised home treatment algorithm for Fabry disease: influence of antibody formation.B E Smid et al.Molecular genetics and metabolism, 108(2), 132-137 (2013-01-22)
Clinical problem-solving. In the thick of it.Deepak A Rao et al.The New England journal of medicine, 368(18), 1732-1738 (2013-05-03)
Successful desensitization to agalsidase beta after anaphylaxis.Neetu Talreja et al.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 112(1), 71-72 (2013-12-18)
Alpha-galactosidase A activity levels in Turkish male hemodialysis patients.Sema Kalkan Uçar et al.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 16(6), 560-565 (2012-11-30)
Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial.Giovanni Di Nardo et al.BMC gastroenterology, 13, 142-142 (2013-09-26)
Angiokeratomas - When is a few too many?Colm O'Mahony et al.International journal of STD & AIDS, 25(5), 378-379 (2013-10-10)
Cloning, heterologous expression, and characterization of novel protease-resistant α-galactosidase from new Sphingomonas strain.Junpei Zhou et al.Journal of microbiology and biotechnology, 22(11), 1532-1539 (2012-11-06)
Improving the binding capacity of Ni2+ decorated porous magnetic silica spheres for histidine-rich protein separation.M Benelmekki et al.Colloids and surfaces. B, Biointerfaces, 101, 370-375 (2012-09-27)
Streptococcus danieliae sp. nov., a novel bacterium isolated from the caecum of a mouse.Thomas Clavel et al.Archives of microbiology, 195(1), 43-49 (2012-10-12)
备注
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).
名称 | CAS号 |
---|

相关产品
相关资讯
问
热门标签
询 单
请 填 写 相 关 信 息
- 请填写产品名称!
- CAS号
- 请正确填写公司名称!
- 请正确填写联系人!
- 请正确填写联系电话!
- 请正确填写联系邮箱!
- 请描述您的问题!